Skip to content

A study to evaluate the efficacy of bodhivriksha (Ficus Religiosa) kashaya basti in the management of vatarakta w.s.r. gouty arthritis

An open label randomized controlled trial to evaluate the efficacy of bodhivriksha (Ficus Religiosa) kashaya basti in the management of vatarakta w.s.r. to gouty arthritis - Nill

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/077694
Enrollment
60
Registered
2024-12-05
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M959- Acquired deformity of musculoskeletal system, unspecified

Interventions

None listed

Sponsors

Institute for ayurved studies and research Shri krishana AYUSH university
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients willing to sign the conset form. Patient between the age sub-group of 30-60 years of either sex. Patients presenting with clinical features of vatarakta. Assessment of gouty arthritis by assessment criteria.(ARA criteria and ACR and EULAR criteria) Patient with chronicity of disease less than 2 years. Patients fit for basti karma (basti yogya). Serum uric acid range 6.00 mg/dl to 9.00 mg/dl.

Exclusion criteria

Exclusion criteria: Subjects with chronicity of disease more than 2 years. Subjects of either sex age below 30 years and above 60 years. The patients unfit for Basti Karma. Patients having systematic pathologies like cardiac disease and hypertension. Subjects with uncontrolled diabetes, systemic disorders and endocrine disorders. Patients having tuberculosis of spine, spinal tumors, vertebral fractures, surgical conditions, and auto immune disease like ankylosing spondylitis. Both groups: Rectal prolapse, Fever, Pregnant and lactating mothers etc. Known case of Rheumatoid Arthritis, Psoriatic Arthritis, Patients with renal or hepatic impairment Serum creatinine more than 1.8mg/dl along with Serum Urea more than 60 mg/dl. Patients requiring emergency treatment

Design outcomes

Primary

MeasureTime frame
The proportion of patients showing improvement in the level of sr. uric acid post Basti karma.Timepoint: Ist- 0 Day. IInd - After the completion of trial. IIIrd- 10 days after Basti karma

Secondary

MeasureTime frame
Reduction in the symptoms of patient like sandhi shotha (swelling), sandhi shool (pain), stadabhta (stiffness) etc. as described in assessment criteria. Reduction in CRP level of the patient. Reduction in ESR level of the patient.Timepoint: Ist- 0 Day. IInd - After the completion of trial. IIIrd- 10 days after Basti karma

Countries

India

Contacts

Public ContactNitish

Institute for ayurved studies and research Shri krishana AYUSH university

drashishhmehta@gmail.com8950375285

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026